In 2020, I was a subject in the Moderna phase III trial for their COVID mRNA vaccine. At the same time, Pfizer-BioNTec trialed a similar mRNA vaccine. Both mRNA vaccines proved highly successful. In both cases, chemically modified mRNA encoding the SARS-CoV-2 spike protein is injected, programming cells that receive the mRNA to produce and secrete spike protein until the mRNA decays.Now, a innovative self-amplifying mRNA vaccine has been approved in Japan has been developed that requires far less modified mRNA:“Self-amplifying mRNA vaccines contain a gene that encodes the spike protein as well as viral genes that code for replicase, the enzyme that serves as a photocopier. So one self-amplifying mRNA molecule can produce many more.”This
Topics:
Joel Eissenberg considers the following as important: COVID vaccines, Healthcare, Hot Topics, self-amplifying mRNA vaccine
This could be interesting, too:
Joel Eissenberg writes Diversity in healthcare delivery
Angry Bear writes Heathcare Insurance Companies Abandoning Medicare Advantage
Bill Haskell writes Review of the Tax Code and Who Benefited the Most from the Breaks in It
Joel Eissenberg writes Access to medical care: right or privilege?
In 2020, I was a subject in the Moderna phase III trial for their COVID mRNA vaccine. At the same time, Pfizer-BioNTec trialed a similar mRNA vaccine. Both mRNA vaccines proved highly successful. In both cases, chemically modified mRNA encoding the SARS-CoV-2 spike protein is injected, programming cells that receive the mRNA to produce and secrete spike protein until the mRNA decays.
Now, a innovative self-amplifying mRNA vaccine has been approved in Japan has been developed that requires far less modified mRNA:
“Self-amplifying mRNA vaccines contain a gene that encodes the spike protein as well as viral genes that code for replicase, the enzyme that serves as a photocopier. So one self-amplifying mRNA molecule can produce many more.”
This self-amplifying mRNA proved to be more effective than the Pfizer-BioNTec vaccine in eliciting a high-titer antibody response.
One concern I have is that the expression of the viral replicase will elicit a T-cell-mediated immune response that will block booster injections by killing cells that express the replicase proteins.
Stephanie Arnett/Mittr | ENVATO